N/A N=69 Training LHDs to Disseminate Evidence-Based Interventions to Small Worksites
Health Behavior
Primary: Number of Worksites — 0; 0; 1.2; 1 Worksites
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma · Stage IV Prostate Cancer AJCC v7
Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants
Phase 2 N=340 A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
SARS-CoV-2
Primary: Parts A and B: Number of Participants With Solicited Local and Solicited Systemic Reactogenicity Adverse Reactions (ARs) — 30; 40; 37; 28 Participants
Phase 2 N=100 Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
High Risk Myelodysplastic Syndrome
Primary: Number of Participants With a Complete Response (CR) — 25 Participants
N/A N=12 Comparing MRI to CT on Pediatric Craniosynostosis.
Craniosynostosis
Primary: Number of Participants With 90% or Greater Concordance Between ZTE and CT Imaging Diagnosis — 9 Participants
N/A N=16 Diet Induced Intestinal Mucosal Adaptation
Healthy Conditions
Primary: Mucosal Surface Enlargement — 10.2; 9.9 percentage of muscular mucosae — p=<0.05
N/A N=4,003 Personalized Recommendations for Acute Kidney Injury (AKI) Care
Acute Kidney Injury
Primary: Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death — 369; 395…
Phase 3 N=453 A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Primary: Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall Population — 7.10; 8.30 months — p=0.468
N/A N=25 Individualized Closed Loop TMS for Working Memory Enhancement
Memory
Primary: Reaction Time Changes During N-Back Task in Responses to Different TMS Frequencies — 0.5853; 0.5978; 0.6012 Seconds — p=0.50
N/A N=7 Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Primary Safety Outcome — 1.4 Percentage of all glucose values
Phase 3 N=432 Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Scalp Psoriasis
Primary: Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8 — 66.4; 27.8 percentage of participants — p=<0.0001
N/A N=232 Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
Cirrhosis
Primary: Avoidable Readmission — 23; 12 Number of Avoidable Readmissions
N/A N=418 Rural Dementia Caregiver Project
Depression · Stress, Psychological · Self Efficacy
Primary: Personal Health Questionnaire Depression (PHQ-8) Scale Score — 5.6; 5.8 units on a scale
N/A N=12 A Study of Overcoming Social Determinants of Health
Social Determinants of Health (SDOH)
Primary: Change in Participant Center for Medicare and Medicaid Services (CMS) Accountable Health Social Determinants of Health (SDOH) Screening Assessment — 6; 5; 9; 5…
N/A N=50 Patient Reported Satisfaction With Contoura LASIK Utilizing the Phorcides Analytic Software
Myopia
Primary: Subject Satisfaction — 50 Participants